NasdaqCM:AVGR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$91.3m

Last Updated

2021/07/27 01:31 UTC

Data Sources

Company Financials +

Executive Summary

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Avinger's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AVGR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: AVGR's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-2.3%

AVGR

3.2%

US Medical Equipment

3.3%

US Market


1 Year Return

122.3%

AVGR

28.9%

US Medical Equipment

37.8%

US Market

Return vs Industry: AVGR exceeded the US Medical Equipment industry which returned 31% over the past year.

Return vs Market: AVGR exceeded the US Market which returned 39.1% over the past year.


Shareholder returns

AVGRIndustryMarket
7 Day-2.3%3.2%3.3%
30 Day-18.2%2.6%1.1%
90 Day-20.9%2.5%2.9%
1 Year122.3%122.3%29.8%28.9%39.9%37.8%
3 Year-92.9%-92.9%73.5%69.4%65.8%55.4%
5 Year-99.9%-99.9%147.2%135.7%124.3%99.4%

Long-Term Price Volatility Vs. Market

How volatile is Avinger's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Avinger undervalued compared to its fair value and its price relative to the market?

4.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVGR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVGR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AVGR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: AVGR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVGR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVGR's PB Ratio (4.5x) is in line with the US Medical Equipment industry average.


Future Growth

How is Avinger forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

0.05%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVGR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVGR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVGR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVGR's revenue (31.1% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: AVGR's revenue (31.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AVGR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Avinger performed over the past 5 years?

22.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVGR is currently unprofitable.

Growing Profit Margin: AVGR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVGR is unprofitable, but has reduced losses over the past 5 years at a rate of 22.7% per year.

Accelerating Growth: Unable to compare AVGR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVGR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).


Return on Equity

High ROE: AVGR has a negative Return on Equity (-88.92%), as it is currently unprofitable.


Financial Health

How is Avinger's financial position?


Financial Position Analysis

Short Term Liabilities: AVGR's short term assets ($37.2M) exceed its short term liabilities ($7.2M).

Long Term Liabilities: AVGR's short term assets ($37.2M) exceed its long term liabilities ($14.4M).


Debt to Equity History and Analysis

Debt Level: AVGR's debt to equity ratio (65.4%) is considered high.

Reducing Debt: AVGR's debt to equity ratio has reduced from 1765.5% to 65.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVGR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AVGR has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 19.6% each year.


Dividend

What is Avinger current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVGR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVGR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average management tenure


CEO

Jeff Soinski (59 yo)

6.58yrs

Tenure

US$504,903

Compensation

Mr. Jeffrey M. Soinski, also known as Jeff, has been Chief Executive Officer, President and Director of Avinger, Inc. since December 29, 2014. From Avinger’s formation in September 2009 until the acquisiti...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD504.90K) is about average for companies of similar size in the US market ($USD545.11K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AVGR's management team is seasoned and experienced (6.6 years average tenure).


Board Members

Experienced Board: AVGR's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.7%.


Top Shareholders

Company Information

Avinger, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Avinger, Inc.
  • Ticker: AVGR
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$91.270m
  • Shares outstanding: 95.35m
  • Website: https://www.avinger.com

Number of Employees


Location

  • Avinger, Inc.
  • 400 Chesapeake Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings


Biography

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial d...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/27 01:31
End of Day Share Price2021/07/26 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.